返回 
加入收藏
曲妥珠单抗联合新辅助化疗对乳腺癌患者术后临床疗效及相关指标的影响
x
请在关注微信后，向客服人员索取文件
| 篇名： | 曲妥珠单抗联合新辅助化疗对乳腺癌患者术后临床疗效及相关指标的影响 |
| TITLE： | |
| 摘要： | 目的：探讨曲妥珠单抗联合新辅助化疗对乳腺癌患者术后临床疗效及血清中血管新生因子、乳腺组织中凋亡分子的影响。方法：选择2012 年1 月－2014 年12 年在我院接受住院治疗的乳腺癌患者116 例作为研究对象，按照随机数表法分为对照组和观察组，各58例。对照组术前给予注射用卡铂100 mg（加入5％葡萄糖注射液稀释至10 mg/mL，再加入500 mL葡萄糖注射液中），于每个化疗周期的第1天ivgtt，200～400 mg/m2 ；多西他赛注射液于每个化疗周期的第1天ivgtt，75 mg/m2。观察组在对照组基础上加用注射用曲妥珠单抗，第1周剂量4 mg/kg，第2～18周剂量为2 mg/kg，每周1次，ivgtt。3周为1个周期，两组患者均持续治疗6个周期，治疗结束2周后行乳腺癌改良根治术。观察两组患者治疗前后血清血管新生因子水平和乳腺组织凋亡分子水平，并比较两组患者治疗结束后1年时的临床疗效及不良反应发生情况。结果：治疗前，两组患者血清血管新生因子和乳腺组织凋亡分子水平比较，差异均无统计学意义（P＞0.05）；治疗后，两组患者血清血管新生因子和乳腺组织凋亡分子水平显著降低，且观察组显著低于对照组，差异均有统计学意义（P＜0.05）。观察组患者临床有效率为82.76％，显著高于对照组的56.90％，差异有统计学意义（P＜0.05）。两组患者不良反应发生率比较，差异无统计学意义（P＞0.05）。结论：曲妥珠单抗联合新辅助化疗有助于提高乳腺癌治疗效果、防止复发，降低血清中血管新生因子及乳腺组织凋亡分子表达水平，且安全性较好。 |
| ABSTRACT： | OBJECTIVE： To investigate the effects of trastuzumab combined with neoadjuvant chemotherapy on clinical efficacy of breast cancer patients， serum angiogenic factors and apoptosis factors of breast tissue. METHODS： A total of 116 breast cancer in patients were selected from our hospital during Jan. 2012-Dec. 2014 as research object， and then divided into control group and observation group according to random number table， with 58 cases in each group. Control group was given Carboplatin for injection 100 mg（added into 500 mL 5％ Glucose injection after diluted into 10 mg/mL）， ivgtt， 200-400 mg/m2 on the first day of each chemotherapy cycle； Docetaxel injection ivgtt，75 mg/m2 on the first day of each chemotherapy cycle. On the basis of control group， observation group was additionally given Trastuzumab for injection， 4 mg/kg in the first week， 2 mg/kg in the 2nd-8th week， once a week， ivgtt. A treatment course lasted for 3 weeks， and both groups received 6 courses of treatment. Both groups received modified radical mastectomy 2 weeks after treatment. The levels of serum angiogenic factors and apoptosis factors of breast tissue were observed in 2 groups before and after treatment. Clinical efficacies and the occurrence of ADR were compared between 2 groups 1 year after treatment. RESULTS： Before treatment， there was no statistical significance in the levels of serum angiogenic factors and apoptosis factors of breast tissue between 2 groups （P＞0.05）. After treatment， the levels of serum angiogenic factors and apoptosis factors of breast tissue were decreased significantly in 2 groups， and the observation group was significantly lower than the control group， with statistical significance （P＜0.05）. Clinical response rate of observation group was 82.76％， which was significantly higher than 56.90％ of control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Trastuzumab combined with neoadjuvant chemotherapy is helpful to improve the therapeutic effect with breast cancer, prevent recnrence， and reduce the expression of serum angiogenic factors and apoptosis factors of breast tissue with good safety. |
| 期刊： | 2017年第28卷第11期 |
| 作者： | 耿凤勇，金克敏 |
| AUTHORS： | GENG Fengyong1，JIN Kemin |
| 关键字： | 乳腺癌；曲妥珠单抗；新辅助化疗；血管新生因子；凋亡相关分子 |
| KEYWORDS： | Breast cancer； Trastuzumab； Neoadjuvant chemotherapy； Angiogenic factors； Apoptosis factors |
| 阅读数： | 317 次 |
| 本月下载数： | 6 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
